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ventromedial hypothalamic nucleus glycogen 
metabolism and glucose‑regulatory signaling
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The catecholamine norepinephrine (NE) links hindbrain metabolic‑sensory neurons with downstream gluco‑regulatory loci, 
including the ventromedial hypothalamic nucleus (VMN). Exogenous NE up‑regulates VMN expression of glutamate decarboxylase 
(GAD), biomarker for the gluco‑inhibitory transmitter γ‑aminobutryic acid (GABA). Brain glycogen phosphorylase (GP)‑muscle 
(GPmm) and ‑brain (GPbb) variants are stimulated in vitro by NE or energy deficiency, respectively. Current research investigated 
whether lactoprivic‑driven VMN NE signaling regulates GABA and if VMN GPmm and GPbb profiles react differently to that deficit 
cue. Male rats were pretreated by caudal fourth ventricle delivery of the selective catecholamine neurotoxin 6‑hydroxydopamine 
(6OHDA) ahead of the monocarboxylate transporter inhibitor alpha‑cyano‑4‑hydroxycinnamic acid (4CIN). Micropunch‑dissected 
VMN tissue was analyzed by Western blot and ELISA to assess NE‑dependent 4CIN regulation of GAD and GP variant protein 
expression and NE activity. 4CIN caused 6OHDA‑reversible augmentation of VMN NE content and plasma glucose and 
counter‑regulatory hormone levels. 6OHDA stimulated basal VMN GAD expression, but prevented 4CIN stimulation of this 
profile. Neurotoxin inhibited or increased baseline VMN GPmm and GPbb levels, respectively, in non‑4CIN‑injected rats. 6OHDA 
deterred 4CIN inhibition of GPmm, but did not prevent drug stimulation of GPbb. Results affirm hindbrain lactoprivic regulation 
of glucostasis. Hindbrain NE exerts opposite effects on VMN GABA transmission during hindbrain lactostasis vs. ‑privation. VMN 
norepinephrine‑ vs. energy‑sensitive GP variants are subject to dissimilar NE regulation during energy homeostasis, and respond 
differently to hindbrain lactoprivation.
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INTRODUCTION
The ventromedial hypothalamic nucleus (VMN) 
utilizes metabolic sensory information in the form of 
nutrient, endocrine, and neurochemical cues to direct 
glucose counter‑regulatory motor functions (Watts 
and Donovan, 2010; 2014). Specialized energy sub‑
strate‑sensitive neurons in the VMN provide a dynamic 
cellular energy readout by augmenting (‘fuel‑inhibit‑
ed’) or decreasing (‘fuel‑excited’) synaptic firing as ox‑
idizable fuel levels dwindle (Oomura et al., 1969; Silver 
and Erecinska, 1998). Detection of neuro‑energetic de‑
ficiency within the mediobasal hypothalamus (MBH), 
which contains the VMN as well as arcuate and tuberal 
hypothalamic nuclei, is critical for optimal contra‑reg‑
ulatory endocrine and hepatic gluconeogenic respons‑
es to hypoglycemia (Borg et al., 1997; 2003). The hypo‑
glycemia‑sensitive glucose‑inhibitory neurotransmit‑
ter γ‑aminobutyric acid (GABA) acts within the MBH 
to control counter‑regulation by diminishing glucagon 
and epinephrine secretory responses to hypoglycemia 
(Chan et al., 2006).
The VMN and other hypothalamic glucose‑reg‑
ulatory loci receive vital metabolic sensory input 
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from hindbrain energy sensors in the form of nor‑
epinephrine (NE) signaling. Dorsal vagal complex 
(DVC) A2 noradrenergic neurons are a likely source 
of such communication as these cells express hypo‑
glycemia‑sensitive metabolic sensory biomarkers, 
e.g., glucokinase, KATP, and 5’‑AMP‑activated protein 
kinase (AMPK) (Briski et al., 2009; Cherian and Briski, 
2011). The oxidizable glycolytic end‑product L‑lac‑
tate is monitored in the hindbrain as a critical met‑
abolic variable. The astrocyte‑neuron lactate shuttle 
hypothesis posits that astrocyte lactate trafficking 
sustains mitochondrial energy production in neurons 
(Broer et al., 1997; Pellerin et al., 1998; Magistretti 
et al., 1993). Pharmacological induction of lactopri‑
vation within the DVC, involving inhibition of local 
monocarboxylate transporter function, is a potent 
stimulus for hyperglycemia (Patil and Briski, 2005). 
During hypoglycemia, DVC lactate deficiency acti‑
vates A2 neurons (Patil and Briski, 2005) and increas‑
es hypothalamic NE activity (Shrestha et al., 2014). 
Hypoglycemic patterns of NE input to the MBH reg‑
ulate GABA release (Beverly et al., 2000; 2001). Our 
recent studies affirm a positive causal relationship 
between NE and VMN GABA as site‑targeted delivery 
of exogenous NE up‑regulates the GABA marker pro‑
tein glutamate decarboxylase65/67 (GAD65/67) (Ibrahim 
et al., 2019). Current research investigated the hy‑
pothesis that metabolic deficit‑propelled NE input to 
the VMN stimulates GABA signaling. Here, groups of 
adult male rats were injected into the caudal fourth 
ventricle (CV4) with the monocarboxylate transport‑
er inhibitor alpha‑cyano‑4‑hydroxycinnamic acid 
(4CIN) or vehicle alone (Patil and Briski, 2005). Micro‑
punch‑dissected VMN tissue was analyzed by Western 
blotting and ELISA methods to determine 4CIN effects 
on VMN GAD65/67 protein expression and NE activity, 
respectively. A subset of subjects in each treatment 
group were pretreated by intra‑CV4 delivery of the 
selective catecholamine neurotoxin 6‑hydroxydopa‑
mine (6OHDA) (Gujar et al., 2013; Tamrakar et al., 2015; 
Alhamami et al., 2018) to verify the role of DVC NE in 
hindbrain lactoprivic regulation of VMN GAD65/67.
The role of hindbrain NE in regulation of hypo‑
thalamic glycogen energy reserve mobilization is un‑
clear. Brain glycogenolysis, which is catalyzed by gly‑
cogen phosphorylase (GP) enzyme activity, increases 
under circumstances of insufficient energy supply 
vs. demand, e.g., seizure, sleep deprivation, and hy‑
poglycemia (Gruetter, 2003; Brown, 2004) to liberate 
glucosyl units for conversion to L‑lactate (Belanger 
et al., 2011; Stobart and Anderson, 2013). Multiple GP 
isoforms are expressed in brain, including muscle‑ 
(GPmm) and brain‑ (GPbb) types, which differ with re‑
spect to cell‑type localization and regulation by phos‑
phorylation and AMP (Nadeau et al., 2018). GPmm and 
‑bb are both expressed in astrocytes, whereas GPbb 
occurs exclusively in neurons. Phosphorylation elic‑
its complete vs. partial activation of GPmm or GPbb, 
whereas GPbb exhibits greater affinity for and sen‑
sitivity to AMP activation relative to GPmm, and re‑
quires AMP binding for optimal enzyme function and 
Km. Cortical astrocyte cell culture models show that 
NE is a potent stimulus for glial glycogenolysis (Fil‑
lenz et al., 1999; Dong et al., 2012). We reported that 
VMN astrocytes express NE‑sensitive alpha1 (α1), al‑
pha2 (α2) and beta1 (β1) adrenergic receptor (AR) pro‑
teins, and that NE inhibits net VMN GP content (Ibra‑
him et al., 2019). Available in vitro studies indicate 
that GPmm mediates noradrenergic augmentation 
of glycogenolysis (Müller et al., 2015), but the role of 
NE in physiological regulation of brain GPmm in vivo 
remains unclear. Cell energy deficits boost GPbb ex‑
pression in vitro (Nadeau et al., 2018). Our work shows 
that exogenous NE causes coincident up‑regulation of 
VMN GPbb and GAD65/67, and that the latter response 
is abolished by interruption of astrocyte substrate 
fuel provision (Mahmood et al., 2019). These findings 
imply that NE may stimulate GABAergic transmission 
by enhancing glycogen‑derived substrate fuel supply, 
but VMN GPbb sensitivity to noradrenergic metabolic 
deficit signaling in vivo has not been investigated. The 
present project addressed the premise that hindbrain 
NE imposes differential control of VMN GPmm vs. 
GPbb protein expression during energy homeostasis, 
and that lactoprivic driven‑NE input elicits dissimilar 
adjustments in these GP variant profiles. 
METHODS
Animals and experimental design
Adult male Sprague‑Dawley rats (3–4 months of 
age) were maintained under a 14 h light : 10 h dark 
lighting schedule (lights on at 05.00 h), and allowed 
free access to standard laboratory rat chow (Harlan 
Teklad LM‑485; Harlan Industries, Madison, WI) and 
tap water. Animals were accustomed to daily handling 
for a minimum of one week before experimentation. 
All protocols were conducted in accordance with NIH 
guidelines for care and use of laboratory animals, un‑
der ULM Institutional Animal Care and Use Commit‑
tee approval. Rats were divided into four treatment 
groups (n=4/group). On study day 1, animals were 
anesthetized with ketamine/xylazine (0.1mL/100 g 
bw ip, 90 mg ketamine: 10 mg xylazine/mL; But‑
ler Schein Inc., Melville, NY), and implanted with 
a 26‑gauge stainless steel cannula (prod no. C315G/
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SPC; Plastics One, Inc., Roanoke, VA) aimed at the cau‑
dal fourth ventricle (CV4) (Briski and Shrestha, 2016). 
After surgery, rats were injected subcutaneously (sc) 
with ketoprofen (1 mg/kg bw) and intramuscularly 
with enrofloxacin (10 mg/0.1 mL), treated by topical 
application of 0.25% bupivacaine to closed incisions, 
then transferred to individual cages. At 9:00 h on days 
7 and 9, groups 1 (n=4) and 3 (n=4) were injected into 
the CV4 with vehicle (v), e.g., sterile apyrogenic wa‑
ter containing 0.2% ascorbic acid, while groups 2 
(n=4) and 4 (n=4) rats received 6‑hydroxydopamine 
(6OHDA; 75 ug/1.0 µL (Gujar et al., 2014; Tamrakar et 
al., 2015; Alhamami et al., 2018). Beginning at 9:00 h 
on day 10, animals in groups 1 and 2 were infused into 
CV4 with vehicle (60% DMSO : 40% 0.9% NaCl; 2.0 µL), 
over a 30 min period using a 33‑gauge internal injec‑
tion cannula (prod. no. C315I/SPC; Plastics One). At 
the same time, rats in groups 3 and 4 were treated 
with 4‑CIN (75.0 ug/2.0 µL (Patil and Briski, 2005). An‑
imals were sacrificed at 11:00 h on day 10 for blood 
and brain tissue collection. Dissected brains were 
immediately snap‑frozen in liquid nitrogen‑cooled 
isopentane and stored in ‑80°C. Plasma was stored at 
‑20°C.
Western blot analysis of VMN glycogen enzyme 
protein expression
Forebrains were cut into consecutive 200 μm ‑ 
thick frozen sections through the VMN (‑1.78 to 
‑3.25 mm). Calibrated hollow punch tools (prod. no. 
57401; Stoelting; Kiel, WI) were used to bilaterally 
dissect VMN tissue for immunoblotting (right‑side 
VMN punches were collected into lysis buffer consist‑
ing of 2.0% sodium dodecyl sulfate, 0.05 M dithioth‑
reitol, 10.0% glycerol, 1.0 mM EDTA, 60 mM Tris‑HCl, 
pH 7.2) or for NE ELISA (left‑side VMN punches were 
collected into 0.01 N HCl supplemented with 1.0 mM 
EDTA, 4.0 mM sodium metabisulfite). For each protein 
of interest, heat‑denatured tissue aliquots from indi‑
vidual subjects were combined within each treatment 
group to create triplicate pools ahead of separation 
in Bio‑Rad TGX 10–12% Stain‑Free gels (Shakya et 
al., 2018). After electrophoresis, gels were activated 
(1 min) by UV light in a Bio‑Rad ChemiDoc MP Imag‑
ing System (prod. no. 17001395; Hercules, CA) prior 
to overnight protein transblotting (30 V; 4°C; Tow‑
bin buffer) to 0.45‑μm PVDF‑Plus membranes (prod. 
no. PV4HY00010; ThermoFisherScientific, Waltham, 
MA). Membranes were blocked with Tris‑buffer saline 
(TBS), pH 7.4), containing 0.1% Tween‑20 and 2.0% bo‑
vine serum albumin prior to primary antibody incuba‑
tion at 4oC for 24 ‑ 36 hours. Proteins of interest were 
probed with antisera raised in rabbit against glyco‑
gen synthase (GS; prod. no. 3893S, 1:2,000; Cell Signal‑
ing Technology, Danvers, MA), GPmm (1:2,000; prod. 
no. NBP2‑16689; Novus Biologicals, Littleton, CO), 
GPbb (prod. no. NBP1‑32799, 1:2,000; Novus Biol.), or 
GAD65/67 (1:10,000; prod. no. ABN904; MilliporeSigma, 
Burlington, MA), as described (Ali et al., 2019; Bris‑
ki and Mandal, 2019; Napit et al., 2019). Membranes 
were incubated for 1 h with a peroxidase‑conjugated 
goat anti‑rabbit (NEF812001EA, 1:5,000; PerkinElmer, 
Waltham, MA) secondary antiserum prior to expo‑
sure to Supersignal West Femto maximum sensitivity 
chemiluminescent substrate (prod. no. 34096; Ther‑
moFisherScientific). Membrane buffer washes and 
antibody incubations were carried out by Freedom 
Rocker™ Blotlbot® automation (Next Advance, Inc., 
Troy NY). Protein band chemiluminescence optical 
density (O.D.) values were obtained in the ChemiDoc 
MP system, and normalized to individual‑lane total 
protein using Imagelab software (Image LabTM 6.0.0; 
BioRad). Precision plus protein molecular weight dual 
color standards (prod. no. 161‑0374; Bio‑Rad) were in‑
cluded in each Western blot analysis.
For each animal, micropunched VMN tissue was an‑
alyzed for NE content using Noradrenaline Research 
ELISATM kit reagents (Labor Diagnostika Nord GmbH & 
Co KG, Nordhorn, Germany), as reported (Shrestha et 
al., 2014). 
Western blot analysis of DVC dopamine‑
‑beta‑hydroxylase (DβH) protein expression
DVC A2 area tissue was bilaterally micropunch‑dis‑
sected from serial 100 μm‑thick frozen sections cut 
between ‑14.36 and ‑14.86 mm posterior to bregma. 
Triplicate tissue lysate pools from each treatment 
group were analyzed by Stain‑Free Western blotting, 
as described above, using a rabbit polyclonal anti‑DβH 
antiserum (1:1000; prod. no. sc‑15318; Santa Cruz Bio‑
technology, Santa Cruz, CA), as described (Ibrahim 
and Briski, 2014; Briski and Shrestha, 2016; Alenazi et 
al., 2016). Protein molecular weight markers were in‑
cluded in each Western blot analysis.
Statistical analyses 
Mean normalized protein O.D., NE, and plasma 
glucose, glucagon, and corticosterone measures were 
evaluated between treatment groups by two‑way an‑
alysis of variance and Student Newman Keuls post hoc 
test. Differences of p<0.05 were considered signifi‑
cant.
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RESULTS
Fig. 1 illustrates effects of intra‑CV4 adminis‑
tration of the monocarboxylate transporter in‑
hibitor 4CIN on VMN GAD65/67 protein expression 
(Fig. 1A; F(3,9)=16.52; p<0.0001) and NE content (Fig. 2B; 
F(3,9)=27.36; p=0.0001) in animals that were pretreated 
by the neurotoxin 6OHDA vs. vehicle administration 
to the CV4. Data show that 6OHDA exposure signifi‑
cantly enhanced GAD65/67 levels compared to V‑pre‑
treated controls (6OHDA/V vs. V/V) (Fig. 1A). This 
protein profile was also augmented by 4CIN (V/4CIN 
vs. V/V). Stimulatory effects of 4CIN on GAD65/67 ex‑
pression were abolished by 6OHDA (6OHDA/4CIN vs. 
6OHDA/V). 6OHDA caused a significant reduction in 
VMN NE accumulation. VMN NE activity was ampli‑
fied by 4CIN; this response was abolished by prior 
neurotoxin exposure. 
Fig. 2 depicts effects of 6OHDA on expression lev‑
els of VMN GS (Fig. 2A; F(3,9)=4.80; p=0.03) and the GP 
variants GPmm (Fig. 2B; F(3,9)=15.20; p=0.0002) and GPbb 
(Fig. 2C; F(3,9)=47.15; p<0.0001) following CV4 adminis‑
tration of 4CIN. As shown in Fig. 2A, 6OHDA elevat‑
ed baseline VMN GS protein expression. 4CIN alone 
did not alter GS profiles, but this treatment reversed 
neurotoxin augmentation of GS content 6OHDA sig‑
nificantly inhibited VMN GPmm protein expression 
(Fig. 2B). This protein profile was also diminished 
after 4CIN administration to V‑pretreated rats; this 
suppressive drug effect was abolished by 6OHDA pre‑
treatment. The 6OHDA/V treatment group exhibited 
up‑regulated VMN GPbb content (Fig. 2C). 4CIN ad‑
ministration significantly enhanced GPbb expression 
in both vehicle‑ and 6OHDA‑pretreated groups. 
Neurotoxin effects on DVC A2 area DβH protein 
content are shown in Fig. 3 (F(3,9)=9.09; p=0.0004). Re‑
sults indicate that DβH expression did not differ be‑
tween 6OHDA/V and V/V treatment groups, but that 
4CIN augmentation of this protein profile was prevent‑
ed by neurotoxin pretreatment. 
Effects of 6OHDA on plasma glucose (Fig. 4A; 
F(3,12)=5.20; p=0.03), glucagon (Fig. 4B; F(3,12)=6.55; p=0.02), 
and corticosterone (Fig. 4C; F(3,12)=18.80; p=0.0006) re‑
sponses to 4CIN are shown in Fig. 4. 6OHDA did not 
modify baseline circuiting glucose or counter‑regu‑
latory hormone concentrations. However, neurotoxin 
pretreatment abolished hindbrain lactoprivic stimula‑
tion of these plasma profiles.
DISCUSSION
Current research expanded upon recent evi‑
dence for exogenous NE regulation of VMN GPbb and 
GAD65/67 protein expression (Mahmood et al., 2019) to 
investigate whether endogenous noradrenergic sig‑
naling is involved in physiological regulation of VMN 
glucose‑regulatory and glycogen metabolic function. 
Outcomes demonstrate that homeostatic and lacto‑
privic patterns of DVC A2 noradrenergic signaling 
impose distinctive regulatory effects on VMN glu‑
co‑inhibitory GABAergic transmission and GP vari‑
ant expression. Results show that pharmacological 
hindbrain lactoprivation elevates VMN NE activity 
relative to baseline. Metabolic status‑dependent NE 
stimulus strength is correlated with differential ad‑
justments in VMN GAD65/67 and NE‑sensitive GPmm 
expression; further effort is required to elucidate the 
Fig. 1. Effects of pharmacological hindbrain lactoprivation on vmn glutamate decarboxylase65/67 (GAD65/67) protein expression and norepinephrine (NE) 
tissue content in vehicle (V) vs. 6OHDA‑pretreated male rats. Data in Fig. 1A depict mean VMN GAD65/67 O.D. measures + S.E.M. for V/V, 6OHDA/V, V/4CIN, 
and 6OHDA/4CIN treatment groups. Fig. 1B shows mean VMN NE tissue content ± S.E.M. for the same groups. *p<0.05; **p<0.01; ***p<0.001.
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mechanisms that may underlie bi‑directional norad‑
renergic regulation of these proteins. Baseline NE in‑
put diminishes VMN energy‑sensitive GPbb profiles, 
but lactoprivation augments this GP variant via cat‑
echolaminergic‑independent cues. Inverse lactopriv‑
ic regulation of VMN GPmm and GPbb expression is 
presumed to facilitate energy deficit‑ as opposed to 
neurotransmitter‑mediated control of local glyco‑
gen breakdown. Present observations that hindbrain 
lactoprivation elicits hyperglycemia and stimulates 
counter‑regulatory hormone secretion affirm hind‑
brain metabolic sensor involvement in neural regula‑
tion of glucostasis.
Current findings provide novel evidence that DVC 
noradrenergic signaling may inhibit VMN GABAergic 
transmission during energy homeostasis. It remains 
to be determined if down‑regulated GABA release di‑
minishes local gluco‑inhibitory tone during glucosta‑
sis, or alternatively, whether GABA suppression of 
counter‑regulation is characteristic of states of met‑
abolic dys‑equilibrium. The latter scenario cannot be 
discounted as investigation of effects of pharmaco‑
logical GABA receptor inhibition on counter‑regulato‑
ry outflow has been performed in hypoglycemic, but 
not euglycemic rats (Chan et al., 2006; 2013). Present 
data show that 4CIN‑induced hindbrain lactoprivation 
up‑regulates VMN GAD65/67 protein expression in male 
rats. Deterrence of this positive response to 4CIN by 
neurotoxin pretreatment implies that noradrenergic 
transmission is required for this drug action. Results 
provide original proof that hindbrain NE may exert 
bi‑directional, signal strength (e.g., metabolic status) 
‑ dependent effects on VMN GABA transmission. The 
mechanisms that underlie these divergent effects of 
baseline vs. enhanced noradrenergic input on this glu‑
co‑regulatory neurotransmitter remain unclear.
Fig.  3. Effects of 6OHDA pretreatment on dorsal vagal complex A2 cell 
area dopamine‑beta‑hydroxylase (DβH) protein expression in vehicle (V) 
vs. 4CIN‑injected animals. Data depict mean normalized tissue DβH O.D. 
measures ± S.E.M. for V/V (solid white bars), 6OHDA/V (solid gray bars), 
V/4CIN (diagonal‑striped white bars), and 6OHDA/4CIN (diagonal‑striped 
gray bars) treatment groups. *p<0.05; **p<0.01; ***p<0.001.
Fig. 2. Effects of precedent catecholaminergic neurotoxin exposure on ventromedial hypothalamic nucleus (VMN) glycogen metabolic enzyme protein 
responses to caudal fourth ventricular (CV4) administration of the monocarboxylate transporter inhibitor alpha‑cyano‑4‑hydroxycinnamic acid (4CIN). 
Groups of male rats were injected into the CV4 with vehicle (V; groups 1 (n=4) and 3 (n=4) or the neurotoxin 6‑hydroxydopamine (6OHDA; 75 ug/1.0 µL; 
groups 2 (n=4) and 4 (n=4) at ‑24 and ‑72 prior to to. At to, animals received intra‑CV4 injections of V (groups 1 and 2) or 4CIN (75 ug/2.0 uL; groups 3 
and 4). Micropunched VMN tissue was analyzed by Western blot for glycogen synthase (GS; Fig. 2A), glycogen phosphorylase‑muscle type (GPmm; Fig. 2B), 
or glycogen phosphorylase‑brain type (GPbb; Fig. 2C). Data depict mean normalized protein optical density (O.D.) measures ± S.E.M. for the following 
treatment groups: V/V (solid white bars); 6OHDA/V (solid gray bars); V/4CIN (diagonal‑striped white bars); 6OHDA/4CIN (diagonal‑striped gray bars). 
*p<0.05; **p<0.01; ***p<0.001.
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Previous studies in our laboratory showed that in 
male rats, whole VMN GAD65/67 profiles are, depending 
upon insulin dosage, either refractory to (Mahmood 
et al., 2018; 10.0 U neutral protamine Hagedorn insu‑
lin (NPH)/kg bw, sc) or decreased (Mandal and Briski, 
2018; 5.0 U NPH/kg bw, sc) in response to the system‑
ic metabolic stress of bolus insulin injection‑induced 
hypoglycemia. It should be noted that disparate out‑
comes from prior vs. current work credibly point to‑
ward differences between experimental models, in‑
cluding pharmacological activation of a single meta‑
bolic sensory cell population, e.g., hindbrain A2 neu‑
rons, vs. hypoglycemia‑associated body‑wide sensor 
activation. Under the latter circumstances, norad‑
renergic stimulation of GAD65/67 expression may be at‑
tenuated by neurotransmitter cues provided by other 
energy sensors to the VMN. In light of evidence that 
direction of change in VMN NE activity in hypoglyce‑
mic animals depends upon NPH dosage (Alhamami et 
al., 2018), it is possible that magnitude of metabolic 
deficit‑driven NE input to the VMN may be a critical 
determinant to GABA response to hypoglycemia.
Work involving astrocyte cell culture models bol‑
sters the novel concept that brain GP variants exhib‑
it differential reactivity to distinctive physiological 
stimuli, thereby endowing discriminative glycogen 
reactivity to specific regulatory signals (Müller et al., 
2015). Data here document divergent effects of bas‑
al and lactoprivic NE signaling on VMN GPmm versus 
GPbb protein expression in vivo. 6OHDA‑induced aug‑
mentation of GPbb alongside inhibition of GPmm pro‑
files in non‑4CIN – treated rats indicates that VMN en‑
ergy‑sensitive GPbb expression is suppressed by basal 
noradrenergic input, whereas NE‑sensitive GPmm is 
enhanced by the same signal. 4CIN elevated VMN GPbb, 
but inhibited GPmm protein, implying that hindbrain 
lactoprivation stimulates GPbb while decreasing GPmm 
protein levels in that structure. Neurotoxin pretreat‑
ment did not prevent 4CIN augmentation of GPbb, but 
blocked drug suppression of GPmm. Results indicate 
that increasing NE input from basal to lactoprivic levels 
changes the direction of regulatory effect, e.g., stimula‑
tory to inhibitory, on GPmm. NE‑mediated suppression 
of the NE‑responsive GP variant may have the effect of 
sparing glycogen mobilization in the absence of VMN 
energy deficiency. At the same time, hindbrain lacto‑
privation augmented VMN levels of the energy‑sensi‑
tive GP variant GPbb, an outcome that is presumed to 
facilitate glycogen breakdown when energy is insuf‑
ficient. It is notable that lactoprivation up‑regulates 
GPbb via non‑noradrenergic mechanisms, an action 
that could involve lactoprivic patterns of A2 nerve cell 
release of co‑expressed non‑catecholaminergic trans‑
mitters or, alternatively, signaling by lactoprivic‑sensi‑
tive non‑catecholaminergic hindbrain neurons. Further 
research is needed to compare rates and magnitude of 
VMN glycogen mobilization in response to homeostatic 
versus hypoglycemic patterns of hindbrain NE input, 
and to determine if lactoprivic cues from the hindbrain 
are a major determinant of glycogen dissolution during 
hypoglycemia. Additional work is required to investi‑
gate the mechanisms that mediate bi‑directional ef‑
fects of baseline versus lactoprivic hindbrain signaling 
on VMN GPmm expression. In light of evidence that NE 
regulates VMN astrocyte α2 and β1 AR protein profiles 
(Ibrahim et al., 2019), it is speculative that effects of 
distinctive NE stimulus strength on this GP variant may 
involve, in part, adjustments in ratio of expressed AR 
proteins and corresponding changes in post‑receptor 
signal transduction.
Fig. 4. Hindbrain lactoprivic regulation of plasma glucose and counter‑regulatory hormone concentrations; impact of 6OHDA pretreatment. Mean plasma 
glucose (Fig. 4A), glucagon (Fig. 4B), and corticosterone (Fig. 4C) levels ± S.E.M. are presented for V/V, 6OHDA/V, V/4CIN, and 6OHDA/4CIN treatment 
groups. *p<0.05; **p<0.01; ***p<0.001.
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Earlier research documented parallel up‑regula‑
tion of GPbb and GAD65/67 by intra‑VMN administration 
of NE, and reliance of this positive GAD65/67 response to 
NE on astrocyte substrate fuel provision (Mahmood et 
al., 2019). Here, homeostatic patterns of hindbrain NE 
input to the VMN were inhibitory to both GPbb and 
GAD65/67, whereas lactoprivic‑driven NE noradrenergic 
signaling, which was elevated above baseline, stim‑
ulated GAD65/67 but not GPbb expression. It might be 
that greater increments in magnitude of NE activity 
are required to enhance this GP variant. At the same 
time, GPmm and GAD65/67 expression patterns under‑
went inverse adjustments in response to 6OHDA or 
4CIN, via NE‑dependent mechanisms. These findings 
do not constitute definitive proof of a causal relation‑
ship between one or both GP variants and GAD65/67, but 
emphasize the need for further effort to explore this 
possibility.
Observations here of significant diminution of 
baseline VMN tissue NE content in 6OHDA – treat‑
ed rats affirm that DVC A2 neurons are a principal 
source of noradrenergic innervation to that structure 
during energy homeostasis. Data also show that 4CIN 
increased VMN NE activity and that this response 
was prevented by 6OHDA. In earlier studies involving 
a lesser dosage of 4CIN, a net reduction in VMN NE 
content was detected at +2 h (Briski and Mandal, 2019), 
the time point utilized here. As 4CIN elicits dose‑pro‑
portionate Fos expression in multiple hypothalamic 
gluco‑regulatory loci, including the VMN (Briski and 
Patil, 2005), we presume that noradrenergic lactopriv‑
ic signaling may likely increase corresponding to drug 
dosage strength. Since the lower 4CIN dose suppressed 
VMN GAD65/67 and GPmm profiles (responses similar to 
outcomes described here), it is likely reductions in NE 
content observed at +2 h after administration of that 
dosage succeeded an earlier elevation in NE activity in 
that site. Here, prevention of 4CIN‑induced increases 
in VMN NE accumulation by 6OHDA verifies that DVC 
A2 cells respond to lactoprivation by enhancing NE 
transmission to the VMN.
Our previous work demonstrated that the 6OHDA 
protocol used here consistently causes significant 
diminution of numbers of tyrosine hydroxylase‑im‑
munopositive neurons in the DVC A2 area (Gujar et al., 
2014; Tamrakar et al., 2015; Alhamami et al., 2018). As 
immunocytochemical data do not shed light on residu‑
al activity of surviving A2 neurons, Western blot anal‑
ysis of the rate‑limiting catecholamine biosynthetic 
enzyme DβH expression was performed here to assess 
basal and 4CIN‑associated patterns of noradrenergic 
signaling after neurotoxin exposure. Although 6OHDA 
was predicted to decrease A2 area tissue DβH levels, 
current results show that mean protein content did 
not differ between neurotoxin‑ versus vehicle‑pre‑
treated groups. However, lactoprivic intensification 
of DβH expression was prevented by 6OHDA pretreat‑
ment. These outcomes suggest that neurotoxin‑resil‑
ient A2 neurons may up‑regulate this protein profile 
as an adaptive response to reductions in cell popula‑
tion size. Yet, 6OHDA‑associated suppression of VMN 
NE accumulation in vehicle‑ and 4CIN‑treated animals 
implies that baseline and stimulus‑induced neuro‑
transmission by surviving A2 nerve cells is signifi‑
cantly impaired.
Results show that 6OHDA did not modify baseline 
plasma glucose, glucagon, or corticosterone concen‑
trations, but did prevent 4CIN augmentation of circu‑
lating glucose and counter‑regulatory hormone levels. 
These data imply that during energy stability, baseline 
hindbrain noradrenergic input may be one of several 
parallel, redundant cues that regulate glucostasis, so 
that that silencing of this specific signal does not sig‑
nificantly alter blood glucose levels. Yet, augmented NE 
transmission due to lactoprivation is correlated with 
elevated plasma glucose, glucagon, and corticosterone 
levels, outcomes previous reported by our laboratory 
(Gujar et al., 2014), findings confirm that prior reports 
that hindbrain lactate status has a critical impact on 
shaping glycemic responses to insulin administration 
(Patil and Briski, 2005). Coincident drug‑induced hy‑
perglycemia and up‑regulated counter‑regulatory hor‑
mone secretion supports the likelihood that the former 
may tamper the latter responses.
In summary, current research documents differen‑
tial effects of homeostatic versus lactoprivic, e.g., aug‑
mented VMN NE activity patterns on VMN gluco‑in‑
hibitory GABAergic transmission and GP variant ex‑
pression. Additional work will be necessary to identify 
mechanisms that mediate physiological bi‑directional 
noradrenergic regulation of these proteins. Baseline NE 
input was observed to elevate VMN NE‑sensitive GPmm 
and suppress energy‑sensitive GPbb profiles, but the 
latter protein was up‑regulated during hindbrain lacto‑
privation by NE‑independent cues. Opposing effects of 
hindbrain lactoprivation on VMN GPmm and GPbb ex‑
pression may promote facilitate energy deficit‑ vs. neu‑
rotransmitter‑regulation of glycogen disassembly in 
that site. Present evidence that hindbrain lactopriva‑
tion causes hyperglycemia and increases counter‑regu‑
latory hormone secretion bolsters hindbrain metabolic 
sensor involvement in neural regulation of glucostasis. 
Further studies are needed to examine whether lacto‑
privic augmentation of VMN GABA signaling reflects 
GABA neuron metabolic stability due to NE‑dependent 
(e.g., direct noradrenergic input to these neurons) as 
well as NE‑independent, e.g., GPbb‑mediated glycogen 
liberation of oxidizable substrate fuel.
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